Author: Tristero Research; Compiler: Plain Language Blockchain
In September 2025, the U.S. crypto market suddenly changed. For years, launching a new fund meant navigating a 240-day regulatory purgatory. Each product was a customized battle with the U.S. Securities and Exchange Commission (SEC). Then, with a single vote, the SEC replaced the old rulebook with a stopwatch.
By approving universal listing standards for commodity trust shares, the SEC has paved a fast track for crypto trading platform traded products (ETPs). What used to take eight months now takes only two. The result: a deadline traffic jam, with more than a dozen alternative token ETFs, from Solana to Dogecoin, all queued up for a decision within the same narrow window. Welcome to ETF Month. The New Rules of the Game Previously, crypto ETFs required a "19b-4" rule change—each a custom request. The new system eliminates that step for assets that pass a clear, rules-based test. The "golden ticket"—the financial world's "TSA PreCheck"—is a futures market regulated by the U.S. Commodity Futures Trading Commission (CFTC) with at least six months of trading history.
This test has created a de facto cryptocurrency caste system:
The first tier: Bitcoin and Ethereum, which already have spot ETFs that are making a splash.
The second tier: assets like Solana, XRP, and Cardano, which have futures markets that have unlocked the fast lane.
The third tier: everything else, which remains stuck in the slow lane.
This is a shift from “regulation through enforcement” to “regulation through infrastructure.” The SEC no longer debates a currency’s utility, but rather asks: Is it traded in a mature, regulated market?
October Schedule
The new regulations have spawned a packed October schedule:
October 10: Grayscale Trust conversion (Solana, Litecoin).
October 16: Spot Solana ETF decision (21Shares, Bitwise).
October 18–25: XRP ETF approvals expected, with at least one almost certain to get the green light. Also in the queue are: Cardano (Grayscale's GADA), Dogecoin, Avalanche, and Hedera.